Cochrane · systematic review · CD009624
The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving erythropoiesis‐stimulating agents
Mhaskar, R, Wao, H, Miladinovic, B, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
7
No studies
1
Included studies
NR
No studies 1 · 12.5%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 25%Moderate 2 · 25%High 3 · 37.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Benefits and harms of iron supplementation for chemotherapy‐induced anemia
Population: people diagnosed with chemotherapy‐induced anemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival | no estimate extracted | NR | No studies |
Hematopoietic response | RR 1.17 [1.09, 1.26] | 7 studies · 1712 participants | High |
Red blood cell transfusion | RR 0.74 [0.6, 0.92] | 7 studies · 1719 participants | Moderate Downgraded: imprecision |
Median time to hematopoietic response | HR 0.93 [0.67, 1.28] | 5 studies · 1042 participants | Low Downgraded: imprecision, inconsistency |
Mean change in hemoglobin (better indicated by higher values) | MD 0.48 [0.1, 0.86] | 3 studies · 827 participants | Low Downgraded: imprecision, inconsistency |
Quality of life (better indicated by higher values) | SMD 0.01 | 3 studies · 1124 participants | High |
Thromboembolic events | RR 0.95 [0.54, 1.65] | 3 studies · 783 participants | Moderate Downgraded: imprecision |
Treatment‐related mortality | no estimate extracted | 4 studies · 997 participants | High |